Find a Clinical Trial

DEFENDO Long-Term Follow-Up Study

A long-term extension study to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 Neurotrophic Keratitis who enrolled in the DEFENDO Study

18+

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

18+

Learn more

SEER-2

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

18+

Learn more

POETYK SjS-1

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome (POETYK SjS-1)

18+

Learn more

BALATON

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

18+

Learn more

Belvedere

A Phase IV, Multicenter, Open-label, Single-Arm study of the response to treatment after transition to the port delivery system with Ranibizumab (Susvimotom [Ranibizumab injection]) in patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than Ranibizumab.

50+

Learn more

KPI-012-C-001

A Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants with Persistent Corneal Epithelial Defect (PCED)

18+

Learn more

A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1

An open-label Phase II randomized trial of BNT113 in combination with
pembrolizumab versus pembrolizumab monotherapy as a first line therapy in
patients with unresectable recurrent, or metastatic Head and Neck
Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma
virus 16 (HPV16+) and expresses PD-L1

18+

Learn more

Discovery

Discovery Approach to Ocular Hypertension

No minimum age

Learn more

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

EA3132 - Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

18+

Learn more